Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Colorectal Cancer Management Requires Multidisciplinary Approach

April 7th 2015

In an interview with OncLive, James W. Fleshman Jr, MD, explained how technological advances and a growing commitment to a multidisciplinary approach have impacted the treatment of colorectal cancer.

FDA Label Update Emphasizes Importance of RAS Testing in mCRC

April 7th 2015

For further insight into the evolving role of expanded mutation analysis in mCRC, OncLive interviewed Marwan G. Fakih, MD, the director of Gastrointestinal Medical Oncology at City of Hope.

Controversies in Clinical Care: Questioning Research

March 23rd 2015

Maurie Markman, MD, offers examples of clinical trials where the interpretation of study results is worthy of considerable additional discussion or where justification for the actual conduct of the study can be called into question.

Tivozanib Improves PFS Versus Bevacizumab in NRP-1 Low mCRC

March 10th 2015

Low serum neuropilin-1 may indicate longer progression-free survival with tivozanib compared with bevacizumab as a first-line treatment for patients with metastatic colorectal cancer.

Dr. Cremolini on Identifying Molecular Markers in mCRC

February 25th 2015

Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses the necessary steps researchers must take to identify molecular markers in metastatic colorectal cancer (mCRC).

FDA Accepts NDA for TAS-102 in mCRC

February 24th 2015

The FDA has accepted an NDA for the oral nucleoside TAS-102 as a treatment for patients with refractory metastatic colorectal cancer.

Analysis Confirms Safety of Regorafenib in mCRC Among Best Responders

February 14th 2015

Adverse events among patients with metastatic colorectal cancer who responded best to regorafenib in the phase III CORRECT trial were "broadly similar" to the overall study population.

Final Thoughts on Improving Outcomes in CRC

January 30th 2015

Impact of Vitamin D on Colorectal Cancer Outcomes

January 30th 2015

Molecular Profiling in Colorectal Cancer

January 30th 2015

Measuring Therapeutic Response in Colon Cancer

January 30th 2015

Third-Line Regorafenib and TAS-102 in mCRC

January 30th 2015

Second-Line Therapy for Metastatic CRC

January 30th 2015

Postoperative Therapy for Metastatic CRC

January 30th 2015

Treatment Selection in RAS Wild-Type mCRC

January 30th 2015

Communication Strategies for Newly Diagnosed mCRC

January 30th 2015

Expanded RAS Testing Required in CRC

January 30th 2015

Exercise and Lifestyle Factors in Patients with mCRC

January 30th 2015

Adjuvant Therapy in Stage II Colon Cancer

January 30th 2015

Molecular Testing in Colorectal Cancer

January 30th 2015